The exact influence that COX-2 inhibitors exert on the BCC’s development and/or progression is not yet fully understood [60,61], but careful consideration needs to be carried out, as such drugs carry the risk of varied, multiple adverse skin reactions (from fixed drug eruptions, exanthema and urticarial, to Stevens-Johnson syndrome, toxic epidermal necrolysis or drug-induced vasculitis) and even systemic ones (hypertension, edema or congestive heart failure) [62,63]. Here, PTGS2 is linked to toxic epidermal necrolysis.